129872-50-0

Basic information

• Product Name: 4-(Methylsulfonylamino)benzylamine
• Synonyms: MethanesulfonaMide, N-[4-(aMinoMethyl)phenyl]-
• CAS NO: 129872-50-0
• Molecular Formula: C₈H₁₂N₂O₂S
• Molecular Weight: 200.2581
• Product Categories: Amines and Anilines;Boron, Nitrile, Thio,& TM-Cpds
• Mol File: 129872-50-0.mol

Chemical Properties

• Melting Point: 255-257 °C
• Boiling Point: 353.9 °C at 760 mmHg
• Flash Point: 167.8 °C
• Appearance: /
• Density: 1.335 g/cm³
• PKA: 7.59±0.10(Predicted)
• CAS DataBase Reference: 4-(Methylsulfonylamino)benzylamine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(Methylsulfonylamino)benzylamine(129872-50-0)
• EPA Substance Registry System: 4-(Methylsulfonylamino)benzylamine(129872-50-0)

Safety Data

• Hazardous Substances Data: 129872-50-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
4-(Methylsulfonylamino)benzylamine is used as an intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of new drugs and the improvement of existing ones.
Used in Agrochemical Production:
In the agrochemical industry, 4-(Methylsulfonylamino)benzylamine is used as a key component in the creation of various agrochemicals, enhancing crop protection and yield.
Used in Organic Compounds Synthesis:
MSAB is utilized as a building block in the synthesis of a range of organic compounds, broadening its applications across different chemical sectors.
Used in Disease Treatment:
4-(Methylsulfonylamino)benzylamine has potential applications in the treatment of various diseases, indicating its versatility and importance in medical research and therapeutic development.
Used in Chemical Research and Development:
In the realm of chemical research and development, 4-(Methylsulfonylamino)benzylamine is used to explore and innovate new chemical processes and synthesis techniques, contributing to advancements in the field.

Upstream product

• 36268-67-4 4-((methylsulfonyl)amino)benzonitrile 
• 238427-63-9 tert-butyl N-[[4-(methanesulfonamido)phenyl]methyl]carbamate 
• 18600-42-5 4-nitrobenzylamine hydrochloride 
• 94838-58-1 tert-butyl 4-nitrobenzylcarbamate 
• 94838-55-8 tert-butyl (4-aminobenzyl)carbamate 
• 873-74-5 4-Aminobenzonitrile 

Downstream Products

• 863977-53-1 [4-(4-methanesulfonylamino-benzylsulfamoyl)-phenoxy]-acetic acid tert-butyl ester 
• 900145-06-4 N-{4-[(3-hydrazinocarbonyl-pyridin-2-ylamino)-methyl]-phenyl}-methanesulfonamide 
• 900144-20-9 C₂₂H₂₂N₆O₅S₂ 
• 900144-19-6 C₂₃H₂₄N₆O₅S₂ 
• 910534-86-0 3-(4-t-butyl-phenyl)-N-(4-methanesulfonylamino-benzyl)-2-methyl-propionamide 
• 910534-88-2 2-(4-t-butyl-benzyl)-N-(4-methanesulfonylamino-benzyl)-butyramide 
• 515153-00-1 C₂₅H₂₄N₄O₄S 
• 1190069-66-9 N-{4-[(methylsulfonyl)amino]benzyl}-4-[(trifluoromethyl)thio]benzamide 
• 1207960-97-1 N-(4-[3-(4-trimethylsilanylbenzyl)thioureidomethyl]-phenyl)methanesulfonamide 
• 1207961-00-9 N-(4-[3-(4-ethyldimethylsilanylbenzyl)thioureidomethyl]phenyl)methanesulfonamide 
• 1227946-71-5 3-[5,6-bis(methyloxy)-2-pyridinyl]-N-({4-[(methylsulfonyl)amino]phenyl}methyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[3,2-d]pyrimidine-6-carboxamide 
• 1375102-66-1 C₂₈H₄₁N₃O₄S₂ 
• 1375102-76-3 C₂₆H₃₇N₃O₄S₂ 

Relevant articles and documents

Discovery of carboxyl-containing biaryl ureas as potent RORγt inverse agonists

GSK805 (1) is a potent RORγt inverse agonist, but a drawback of 1 is its low solubility, leading to a limited absorption in high doses. We have explored detailed structure-activity relationship on the amide linker, biaryl and arylsulfonyl moieties of 1 trying to improve solubility while maintaining RORγt activity. As a result, a novel series of carboxyl-containing biaryl urea derivatives was discovered as potent RORγt inverse agonists with improved drug-like properties. Compound 3i showed potent RORγt inhibitory activity and subtype selectivity with an IC50 of 63.8 nM in RORγ FRET assay and 85 nM in cell-based RORγ-GAL4 promotor reporter assay. Reasonable inhibitory activity of 3i was also achieved in mouse Th17 cell differentiation assay (76percent inhibition at 0.3 μM). Moreover, 3i had greatly improved aqueous solubility at pH 7.4 compared to 1, exhibited decent mouse PK profile and demonstrated some in vivo efficacy in an imiquimod-induced psoriasis mice model.

BIARYL UREA DERIVATIVE OR SALT THEREOF, AND MANUFACTURING AND APPLICATION OF SAME

The present invention discloses a biaryl urea RORγt inhibitor, and specifically relates to a biaryl urea derivative, as represented by formula I, with an RORγt inhibiting activity, and a preparation process thereof, and a pharmaceutical composition comprising the compound. Further disclosed is use of the compound for treating an RORγt-related disease.

ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS

The present invention relates to a compound suitable for use as a kinase inhibitor according to general formula (I) [compound (C), herein after], or the N- oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or stereoisomer thereof, formula (I) wherein A, R1, R2, R3, R3', R4, R4', X, Y, Z, T are as defined in the claims. The invention further relates to an in vitro method of inhibiting protein kinase activity which comprises contacting a protein kinase with a compound of formula (I), or the N-oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or stereoisomer thereof. The invention further relates to the compounds of formula (I) per se, as well as to their use as a medicament, and for use or in a method of treatment of a disease mediated by a protein kinase selected from cancer, inflammatory disorders, cardiovascular diseases, viral induced diseases, circulatory diseases, fibro-proliferative diseases and pain sensitization disorders.

Novel non-vanilloid VR1 antagonist of high analgesic effects and its structural requirement for VR1 antagonistic effects

A novel non-vanilloid VR1 antagonist consisting of a new vanilloid equivalent exhibits excellent analgesic effects as well as highly potent antagonistic activities in both capsaicin single channel and calcium uptake assays. In addition, the structural requirement for the vanilloid equivalent of the potent VR1 antagonist has also been elucidated.

Synthesis of novel (aryloxy)propanolamines and related compounds possessing both class II and class III antiarrhythmic activity

Several (aryloxy)propanolamines and related compounds (i.e. 5-13, 16-18, 20-24, 27-33, 35, 37-39, 41, and 42) were synthesized and investigated for their class III electrophysiological activity and class II (β-blocking) effects with use of in vitro and in